Loading...
XHKG1066
Market cap2.66bUSD
Dec 23, Last price  
4.57HKD
1D
1.11%
1Q
-4.19%
Jan 2017
-11.78%
Name

Shandong Weigao Group Medical Polymer Co

Chart & Performance

D1W1MN
XHKG:1066 chart
P/E
9.70
P/S
1.47
EPS
0.44
Div Yield, %
3.54%
Shrs. gr., 5y
0.16%
Rev. gr., 5y
8.47%
Revenues
13.23b
-2.86%
407,823,000569,987,000786,926,0001,095,109,0001,514,367,0001,878,495,0002,462,557,0003,180,577,0003,689,115,0004,613,310,0005,277,827,0005,918,930,0006,730,340,0006,292,641,0008,808,861,00010,364,081,00011,345,252,00013,151,719,00013,619,007,00013,229,453,000
Net income
2.00b
-27.57%
65,888,000102,578,000182,603,000329,342,000482,394,000633,864,000799,072,0003,462,172,000996,486,000387,984,0001,084,948,0001,112,736,0001,105,933,0001,303,162,0001,472,935,0001,844,883,0002,086,783,0002,275,929,0002,764,093,0002,001,906,000
CFO
2.80b
+26.37%
17,440,000118,032,000176,547,000276,211,000437,482,000479,074,000523,511,000620,792,000806,031,000720,174,000711,219,0001,052,770,0001,053,139,0001,267,008,0002,219,196,0002,320,990,0002,696,608,0003,035,163,0002,214,574,0002,798,529,000
Dividend
Oct 18, 20240.10171 HKD/sh
Earnings
Mar 24, 2025

Profile

Shandong Weigao Group Medical Polymer Company Limited engages in the research and development, production, and sale of single-use medical devices in the People's Republic of China. It operates through Medical Device Products, Orthopaedic Products, Interventional Products, Pharma Packaging Products, Blood Management Products, and Others segments. The company offers vascular and non-vascular access infusion devices, infusion sets, syringes, puncture needles, and specialized single-use clinical collection kits; wound sutures, wound healing dressings, and wound cleaning and nonvascular catheter supporting extracorporeal devices; and blood collection, storage, separation, and sterilization equipment. It also provides prefilled syringes and pre-filled flush syringes; blood collection and blood glucose testing devices; and general anesthesia consumables, local anesthesia consumables, anesthesia auxiliary consumables, ICU equipment, and open and minimally invasive surgical equipment. In addition, the company engages in the production and sale of orthopedic devices; tumor and blood vessel interventional instruments; implantation materials and artificial organs; medical PVC granules, plastic packing bags, and carton boxes; industrial automatic equipment and parts; molds; hemodialysis equipment; and type I, type II, and type III medical devices. Further, it is involved in the finance leasing and factoring business; wholesale of type I medical devices, surgical devices, and other disposal medical products; provision of asset management, enterprise consulting, enterprise management advisory services, as well as logistics and storage services, as well as export its products. The company offers its products under the Jierui, Wego Ortho, Yahua, Bangde, and Hai Xing brands. It serves hospitals, blood stations, and other medical units; and distributors. The company was incorporated in 2000 and is based in Weihai, the People's Republic of China.
IPO date
Feb 27, 2004
Employees
12,333
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
13,229,453
-2.86%
13,619,007
3.55%
13,151,719
15.92%
Cost of revenue
11,011,490
10,596,243
10,147,920
Unusual Expense (Income)
NOPBT
2,217,963
3,022,764
3,003,799
NOPBT Margin
16.77%
22.20%
22.84%
Operating Taxes
307,585
424,267
415,093
Tax Rate
13.87%
14.04%
13.82%
NOPAT
1,910,378
2,598,497
2,588,706
Net income
2,001,906
-27.57%
2,764,093
21.45%
2,275,929
9.06%
Dividends
(732,633)
(741,638)
(653,288)
Dividend yield
2.13%
1.28%
1.49%
Proceeds from repurchase of equity
(36,530)
(70,496)
554,564
BB yield
0.11%
0.12%
-1.26%
Debt
Debt current
2,573,337
990,131
624,316
Long-term debt
1,723,248
3,634,666
3,593,939
Deferred revenue
76,736
88,070
Other long-term liabilities
499,505
37,001
522,849
Net debt
(4,934,337)
(4,091,119)
(3,831,273)
Cash flow
Cash from operating activities
2,798,529
2,214,574
3,035,163
CAPEX
(647,577)
(1,116,239)
(1,116,882)
Cash from investing activities
(1,388,592)
(2,568,963)
(1,479,374)
Cash from financing activities
(2,157,858)
(1,020,957)
(538,080)
FCF
1,472,797
761,162
1,373,938
Balance
Cash
7,333,313
7,357,615
7,058,679
Long term investments
1,897,609
1,358,301
990,849
Excess cash
8,569,449
8,034,966
7,391,942
Stockholders' equity
20,628,179
20,529,200
18,303,861
Invested Capital
20,092,078
19,644,776
17,998,019
ROIC
9.62%
13.81%
15.08%
ROCE
7.74%
10.84%
11.73%
EV
Common stock shares outstanding
4,518,901
4,526,649
4,516,323
Price
7.61
-40.64%
12.82
31.76%
9.73
-42.97%
Market cap
34,388,837
-40.74%
58,031,640
32.06%
43,943,823
-42.67%
EV
30,998,084
55,718,187
41,752,909
EBITDA
3,129,667
3,825,276
3,727,612
EV/EBITDA
9.90
14.57
11.20
Interest
272,971
191,401
140,396
Interest/NOPBT
12.31%
6.33%
4.67%